Cefazolin Sodium Solution
Product Images NDC 0264-3103

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Cefazolin Sodium (NDC 0264-3103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by B. Braun Medical Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Diagram 1 (Cefazolin 1g And 2g In Duplex 1)

Diagram 1 (Cefazolin 1g And 2g In Duplex 1)
FDA Label Image

3105-11 Container Label (Cefazolin 1g And 2g In Duplex 10)

3105-11 Container Label (Cefazolin 1g And 2g In Duplex 10)
Cefazolin for Injection USP 2 and Dextrose Injection USP 50mL is a single-dose, iso-osmotic, and nonpyrogenic medication. It should only be used for IV administration after reconstituting the contents of both chambers. The medication contains cefazolin sodium USP, equivalent to 2g cefazolin, and hydrous dextrose USP in water for injection USP. The reconstituted solution must be clear and free from particulate matter before use. The medication must be used within 24 hours if stored at room temperature or within 7 days if stored under refrigeration. The container must not be used in a series connection, nor should additives be introduced into the container. Prior to use, check for minute leaks by squeezing the container. The medication is produced in the USA and Italy and does not contain natural rubber latex, PVC, or DEHP.*
FDA Label Image

Drug Chamber Label (Cefazolin 1g And 2g In Duplex 11)

Drug Chamber Label (Cefazolin 1g And 2g In Duplex 11)
This is a label from a drug chamber. It advises the user to discard the unit if the foil strip is damaged. The foil strip should only be peeled when ready for use, and the drug should be visually inspected prior to reconstitution. The user should refer to the package insert for complete directions for reconstitution and administration.*
FDA Label Image

Diagram 2 (Cefazolin 1g And 2g In Duplex 2)

Diagram 2 (Cefazolin 1g And 2g In Duplex 2)
FDA Label Image

Diagram 3 (Cefazolin 1g And 2g In Duplex 3)

Diagram 3 (Cefazolin 1g And 2g In Duplex 3)
FDA Label Image

Diagram 4 (Cefazolin 1g And 2g In Duplex 4)

Diagram 4 (Cefazolin 1g And 2g In Duplex 4)
FDA Label Image

Diagram 5 (Cefazolin 1g And 2g In Duplex 5)

Diagram 5 (Cefazolin 1g And 2g In Duplex 5)
FDA Label Image

Diagram Of Cefazolin Molecular Structure (Cefazolin 1g And 2g In Duplex 6)

Diagram Of Cefazolin Molecular Structure (Cefazolin 1g And 2g In Duplex 6)
FDA Label Image

Diagram Of Dextrose Molecular Structure (Cefazolin 1g And 2g In Duplex 7)

Diagram Of Dextrose Molecular Structure (Cefazolin 1g And 2g In Duplex 7)
FDA Label Image

3103-11 1g Container Label (Cefazolin 1g And 2g In Duplex 8)

3103-11 1g Container Label (Cefazolin 1g And 2g In Duplex 8)
FDA Label Image

Drug Chamber Label (Cefazolin 1g And 2g In Duplex 9)

Drug Chamber Label (Cefazolin 1g And 2g In Duplex 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.